Sector Gamma AS trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.8% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 335,690 shares of the biopharmaceutical company’s stock after selling 212,700 shares during the quarter. Gilead Sciences comprises approximately 4.1% of Sector Gamma AS’s portfolio, making the stock its 9th biggest position. Sector Gamma AS’s holdings in Gilead Sciences were worth $27,198,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $147,000. Hanson & Doremus Investment Management grew its stake in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $172,000. Institutional investors own 75.95% of the company’s stock.
A number of equities research analysts have issued reports on the company. Leerink Swann boosted their price target on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research note on Thursday, October 19th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Mizuho boosted their price objective on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. CIBC initiated coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating for the company. Finally, Bank of America cut their price objective on Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research note on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $85.03.
Gilead Sciences, Inc. (GILD) opened at $79.02 on Tuesday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a market capitalization of $103,190.00, a P/E ratio of 8.99, a P/E/G ratio of -1.68 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the previous year, the firm earned $2.75 EPS. The firm’s revenue was down 13.2% compared to the same quarter last year. analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were issued a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.63%. Gilead Sciences’s dividend payout ratio is presently 23.66%.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://weekherald.com/2018/01/16/sector-gamma-as-has-27-20-million-position-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.